Can blood plasma treat the coronavirus?
Among the many companies developing drugs, antibodies, and vaccines that might be effective against the novel coronavirus, Takeda is taking a different approach: studying the blood of patients who got infected but survived.
As STAT’s Matthew Herper and Adam Feuerstein report, Takeda has begun work on a plasma-derived therapy, a potential drug made by drawing blood from coronavirus survivors, harvesting the plasma, and then isolating the protective antibodies that kept those patients alive.
It’s not a new idea. Blood transfusions have been used to combat viral outbreaks since at least the Spanish Flu pandemic of 1918. But Takeda’s take on it could prove to be faster in development than other therapeutic approaches, an attractive proposition as the virus spreads around the world.
Read more.
As STAT’s Matthew Herper and Adam Feuerstein report, Takeda has begun work on a plasma-derived therapy, a potential drug made by drawing blood from coronavirus survivors, harvesting the plasma, and then isolating the protective antibodies that kept those patients alive.
It’s not a new idea. Blood transfusions have been used to combat viral outbreaks since at least the Spanish Flu pandemic of 1918. But Takeda’s take on it could prove to be faster in development than other therapeutic approaches, an attractive proposition as the virus spreads around the world.
Read more.
.png)
No hay comentarios:
Publicar un comentario